EndLyz
EndLyz is an early stage biotech company developing disease-modifying therapeutics that restore endo-lysomsomal function to treat neurodegenerative disorders such as Parkinson’s Disease and other dementias.
- What
- Life Sciences
- When
- Jul 2021
- CEO
- Joanna Wolak (CSO)
- Status
- Private
- Investment
- Active
- OSE Board Director
- Craig Fox